What patent covers exenatide extended-release (Bydureon) and who owns it?
Exenatide extended-release (marketed as Bydureon) is associated with patents covering the drug formulation and the extended-release delivery system, as well as related manufacturing and method-of-use claims. The specific patent number(s) and assignee depend on the exact product (e.g., Bydureon versus later reformulations), the country, and the claim type (formulation, method, or device-like delivery aspects).
If you tell me the country (US/EU/UK/Canada) and the brand/generic you mean, I can narrow it to the correct patent family and the likely current owner(s).
When does an exenatide extended-release patent expire in the US?
In the US, patent “expiration” for branded injectables typically depends on:
- The latest (most recently expiring) relevant US patent in the family, and
- Any regulatory exclusivities (which are not the same thing as patent term), such as Hatch-Waxman protections.
For an exact date, you need the specific “Orange Book listed” reference drug entry and the listed US patent numbers for that entry. Without that listing, I can’t give a reliable expiration date for “exenatide extended release” as a whole.
Could generics or biosimilars enter before patent expiry?
For exenatide extended-release, the practical question usually becomes “When can an ANDA generic enter?” rather than “biosimilar,” because exenatide is a small-molecule peptide drug, not a biologic in the usual biosimilar sense.
Generic entry timing is typically constrained by:
- Patent(s) listed for the reference product, and
- Exclusivity windows in addition to patents.
The earliest possible entry date often lines up with the point at which a generic can file a successful Paragraph IV certification and then launch after legal barriers lift—again requiring the exact US patent list for the specific reference product.
Are there “follow-on” products (Bydureon/Bydureon BCise) that change the patent picture?
Yes. Companies sometimes create reformulations (different particle size/vehicle, different injector technology, or changes in the drug product), which can lead to additional patent families being relevant. That means “exenatide extended-release” may have multiple overlapping patent expiration timelines depending on whether you mean:
- Bydureon (older formulation) or
- Bydureon BCise (later autoinjector formulation)
To answer precisely, I need which one you’re asking about.
How do you find the exact patent number and expiration date yourself (US)?
The most reliable approach is to check the FDA’s “Drugs@FDA” and the FDA Orange Book for the specific reference product:
1. Find the FDA Orange Book entry for the branded reference drug.
2. Look under “patents” for the listed US patent numbers.
3. Use those patent numbers to determine the latest expected expiration (and whether any regulatory periods extend effective exclusivity).
If you share the reference drug name and whether you mean the US, I can help map the likely patents to the correct listing categories (composition, method, formulation/delivery).
---
Quick clarification so I can give a concrete answer
Which one do you mean?
- US only or another country?
- Bydureon or Bydureon BCise?
- Do you want the latest patent expiration date, or the specific patent numbers that cover the extended-release formulation/delivery?
Sources
None provided.